用快速周期分析工具可视化风险最小化效果:2012年英国质子泵抑制剂标签变更的初步研究
本研究利用英国THIN数据库中2015年9月前使用五种PPI的成人队列,通过时间图(chronographs)比较2012年4月20日MHRA警告前后骨折和骨质疏松的观察/预期事件信息成分(IC)。结果显示警告后长期PPI使用比例降低4.6%,总体PPI使用比例降低4.1%,骨折的汇总IC从0.024降至-0.141,提示风险最小化措施可能改变了处方行为。
要点
- 时间图可快速可视化PPI标签变更前后的风险最小化效果。
- 2012年MHRA警告后长期PPI使用比例降低4.6%,总体PPI使用比例降低4.1%。
- 骨折汇总IC由警告前0.024降至警告后-0.141,提示观察事件少于预期。
核心结论
- 时间图这一可视化快速分析技术可用于评估风险最小化措施的效果。
- 研究支持处方者在MHRA标签变更后改变了部分行为,如将骨折或骨质疏松风险患者从PPI使用中分流。
研究设计与样本
- 队列研究,纳入英国THIN数据库中2015年9月前使用五种PPI的18岁及以上成人。
- 比较2012年4月20日MHRA警告前后(PRE/POST)开始的药物 episodes,分别评估骨折和骨质疏松。
主要发现
- PRE期PPI使用者1,588,973例,POST期664,601例。
- 长期PPI episodes比例降低4.6%,THIN人群总体PPI使用比例降低4.1%。
- 骨折汇总IC:PRE期0.024(95%CI 0.015至0.33),POST期-0.141(95%CI -0.162至-0.120)。
- PPI开始前骨折IC:PRE期-0.027(95%CI -0.037至-0.017),POST期-0.291(95%CI -0.308至-0.274),提示强通道效应。
- 骨质疏松结果与骨折定性相似。
关键数值与推荐
- 时间图展示观察/预期事件的信息成分(IC)及95%可信区间(CI),按月计算并汇总3年。
- IC>0表示观察事件多于预期事件。
临床怎么用
- 可借鉴时间图方法利用大型医疗数据库快速评估风险最小化措施的实施效果。
- 评估结果有助于设计更全面的风险最小化评价研究。
局限性
- 缺乏混杂控制。
- 结局仅由诊断代码定义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Evaluation of risk minimization (RM) actions is an emerging area of regulatory science, often without tools to rapidly and systematically assess their effectiveness. PURPOSE: The aim of this study was to evaluate whether chronographs, typically used for rapid signal detection in observational longitudinal databases, could be used to visualize RM effectiveness. We evaluated the UK Medicines and Healthcare products Regulatory Agency (MHRA) 2012 proton-pump inhibitors (PPIs) class-wide label change that warned of increased risk of bone fracture, advocated to limit duration of use, and recommended to treat those at risk for osteoporosis according to clinical guidelines. METHODS: The cohort consisted of adults aged 18 years and above prescribed one of the five PPIs available in the UK The Health Improvement Network (THIN) database through September 2015. Four chronographs were compared using drug episodes that started before (PRE) and after (POST) the 20 April 2012 MHRA warning; fracture and osteoporosis were evaluated separately. Chronographs show a measure of observed/expected events, the Information Component (IC) and 95% credibility interval (CI), calculated at monthly time intervals relative to the start date of a prescription, and summed to estimate IC over a 3-year period; IC > 0 indicates observed > expected events. We hypothesized that chronographs may assess RM effectiveness if stratified by PRE/POST an RM intervention such as a label change. RESULTS: There were 1,588,973 and 664,601 PPI users in the PRE and POST periods, respectively. We observed a 4.6% reduction in the proportion of long-term PPI episodes and a 4.1% reduction in the overall proportion of the THIN population using PPIs. Compared with the PRE chronographs, when both visually comparing and when examining the summed ICs for fracture in the POST period, a significant reduction was observed overall (IC = 0.024 [95% CI 0.015 to 0.33] PRE vs - 0.141 [95% CI - 0.162 to - 0.120] POST), suggesting less observed events than expected, and prior to PPI start, suggestive of strong channeling (IC = - 0.027 [95% CI - 0.037 to - 0.017] PRE vs - 0.291 [95% CI - 0.308 to - 0.274] POST). Results were qualitatively similar for osteoporosis. CONCLUSIONS: This pilot demonstrated a novel application of a visual, rapid analysis technique to assess RM effectiveness, and supported a hypothesis that prescribers altered some behaviors after the MHRA label change, such as channeling patients at risk of fracture or osteoporosis away from PPI use and potentially reducing fracture outcomes. Limitations include lack of confounding control and outcomes defined only by diagnosis code. Results demonstrate the potential to use large healthcare databases with chronographs to rapidly assess RM effectiveness, similar to signal detection in pharmacovigilance, and may help design more comprehensive RM evaluation studies.
引用
- Sobel RE, Blackwell W, Fram DM, et al. A Novel Approach to Visualize Risk Minimization Effectiveness: Peeping at the 2012 UK Proton Pump Inhibitor Label Change Using a Rapid Cycle Analysis Tool. Drug Saf. 2019. PMID: 31368080. doi:10.1007/s40264-019-00853-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。